Replimune Group, Inc. REPL

REPL Company Overview

Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company operates within the biotechnology and immuno-oncology industries, with a strategic emphasis on using genetically engineered herpes simplex virus type 1 (HSV-1)–based therapies designed to selectively infect and destroy tumor cells while stimulating systemic anti-tumor immune responses. Replimune’s primary value driver is its proprietary RPx platform, which supports multiple investigational therapies targeting solid tumors and other difficult-to-treat cancers.

The company’s lead product candidate has been RP1, an oncolytic immunotherapy evaluated both as a monotherapy and in combination with immune checkpoint inhibitors such as pembrolizumab. Additional pipeline programs include RP2 and RP3, which are engineered to deliver enhanced immune activation within the tumor microenvironment. Replimune was founded in 2015 by biotechnology executives and scientists with experience in oncology and viral immunotherapy development. Since inception, the company has evolved from an early-stage platform developer into a publicly traded clinical-stage oncology company listed on Nasdaq under the ticker REPL.